Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 ...

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy showed a 60.9% overall response rate, outperforming the 40% ...

Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer. BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical ...

as well as an increase in overall survival (OS), when used as a first-line treatment for colorectal cancer with BRAF V600E mutations. Both results were "clinically meaningful," according to a ...

The BREAKWATER study supports Braftovi-Erbitux-chemo as a new first-line standard-of-care for patients with BRAF V600E-mutant metastatic colorectal cancer, the study researchers said in the ...

"These data from the BREAKWATER study show the potential for this targeted treatment regimen to become the new standard of care for people with BRAF V600E-mutant metastatic colorectal cancer ...

Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF V600E mutation. The regimen demonstrated a 60.9% confirmed ORR ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study.

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has ... the combination in mCRC patients living with a BRAF V600E mutation who are treatment-naive. The top-line data also ...

“These data from the BREAKWATER study show the potential for this targeted treatment regimen to become the new standard of care for people with BRAF V600E -mutant metastatic colorectal cancer, for ...